Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Agalsidase beta as an enzyme replacement therapy (ERT) for Fabry disease facilitates cellular globotriaosylceramide (Gb3) clearance, contributing to reducing the disease burden associated with Fabry disease symptoms.
• The presence of neutralizing anti-drug antibodies (ADAs) in ERT-treated males may reduce the effectiveness of agalsidase beta, potentially leading to disease progression in this subgroup.
• Comparative data between agalsidase beta and agalsidase alpha indicate both therapies aid in Gb3 clearance; however, specific comparative effectiveness outcomes were not detailed in the studies.
• Agalsidase beta therapy is associated with infusion-associated reactions, though specific details of these reactions are not provided.
• The formation of neutralizing anti-drug antibodies (ADAs) in males treated with enzyme replacement therapy for Fabry disease is noted as a safety concern, as it may reduce the therapy's effectiveness and potentially lead to disease progression.